Selected research
Industry Research
Necrotizing Ulcerative Gingivitis (NUG) Industry Research Report 2026
Market perspective
The global Necrotizing Ulcerative Gingivitis (NUG) market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Necrotizing Ulcerative Gingivitis (NUG) market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Necrotizing Ulcerative Gingivitis (NUG) market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Necrotizing Ulcerative Gingivitis (NUG) market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Necrotizing Ulcerative Gingivitis (NUG) include Abbott Laboratories, Eli Lilly and Company, Hindustan Antibiotics, Otsuka Pharmaceutical, GlaxoSmithKline, Mylan, Merck, Novartis and Sanofi and among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Necrotizing Ulcerative Gingivitis (NUG) market in terms of revenue (US$ million) and, where applicable, service volume (K Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Necrotizing Ulcerative Gingivitis (NUG).
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Necrotizing Ulcerative Gingivitis (NUG) Market by Company
Abbott Laboratories
Eli Lilly and Company
Hindustan Antibiotics
Otsuka Pharmaceutical
GlaxoSmithKline
Mylan
Merck
Novartis
Sanofi
Teva Pharmaceutical
Necrotizing Ulcerative Gingivitis (NUG) Segment by Type
Medication
Surgery
Necrotizing Ulcerative Gingivitis (NUG) Segment by Application
Homecare
Pharmacies
Hospitals
Others
Necrotizing Ulcerative Gingivitis (NUG) Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Necrotizing Ulcerative Gingivitis (NUG) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Necrotizing Ulcerative Gingivitis (NUG) and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Necrotizing Ulcerative Gingivitis (NUG).
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Necrotizing Ulcerative Gingivitis (NUG) companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Medication
- Surgery
Applications
- Homecare
- Pharmacies
- Hospitals
- Others
Companies covered
- Abbott Laboratories
- Eli Lilly and Company
- Hindustan Antibiotics
- Otsuka Pharmaceutical
- GlaxoSmithKline
- Mylan
- Merck
- Novartis
- Sanofi
- Teva Pharmaceutical
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Necrotizing Ulcerative Gingivitis (NUG) by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Medication
- 2.2.3 Surgery
- 2.3 Necrotizing Ulcerative Gingivitis (NUG) by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Homecare
- 2.3.3 Pharmacies
- 2.3.4 Hospitals
- 2.3.5 Others
- 2.4 Assumptions and Limitations
3 Necrotizing Ulcerative Gingivitis (NUG) Breakdown Data by Type
- 3.1 Global Necrotizing Ulcerative Gingivitis (NUG) Historic Market Size by Type (2021-2026)
- 3.2 Global Necrotizing Ulcerative Gingivitis (NUG) Forecasted Market Size by Type (2027-2032)
4 Necrotizing Ulcerative Gingivitis (NUG) Breakdown Data by Application
- 4.1 Global Necrotizing Ulcerative Gingivitis (NUG) Historic Market Size by Application (2021-2026)
- 4.2 Global Necrotizing Ulcerative Gingivitis (NUG) Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Necrotizing Ulcerative Gingivitis (NUG) Market Perspective (2021-2032)
- 5.2 Global Necrotizing Ulcerative Gingivitis (NUG) Growth Trends by Region
- 5.2.1 Global Necrotizing Ulcerative Gingivitis (NUG) Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Necrotizing Ulcerative Gingivitis (NUG) Historic Market Size by Region (2021-2026)
- 5.2.3 Necrotizing Ulcerative Gingivitis (NUG) Forecasted Market Size by Region (2027-2032)
- 5.3 Necrotizing Ulcerative Gingivitis (NUG) Market Dynamics
- 5.3.1 Necrotizing Ulcerative Gingivitis (NUG) Industry Trends
- 5.3.2 Necrotizing Ulcerative Gingivitis (NUG) Market Drivers
- 5.3.3 Necrotizing Ulcerative Gingivitis (NUG) Market Challenges
- 5.3.4 Necrotizing Ulcerative Gingivitis (NUG) Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Necrotizing Ulcerative Gingivitis (NUG) Players by Revenue
- 6.1.1 Global Top Necrotizing Ulcerative Gingivitis (NUG) Players by Revenue (2021-2026)
- 6.1.2 Global Necrotizing Ulcerative Gingivitis (NUG) Revenue Market Share by Players (2021-2026)
- 6.2 Global Necrotizing Ulcerative Gingivitis (NUG) Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Necrotizing Ulcerative Gingivitis (NUG) Head Office and Area Served
- 6.4 Global Necrotizing Ulcerative Gingivitis (NUG) Players, Product Type & Application
- 6.5 Global Necrotizing Ulcerative Gingivitis (NUG) Manufacturers Established Date
- 6.6 Global Necrotizing Ulcerative Gingivitis (NUG) Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Necrotizing Ulcerative Gingivitis (NUG) Market Size (2021-2032)
- 7.2 North America Necrotizing Ulcerative Gingivitis (NUG) Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Necrotizing Ulcerative Gingivitis (NUG) Market Size by Country (2021-2026)
- 7.4 North America Necrotizing Ulcerative Gingivitis (NUG) Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Necrotizing Ulcerative Gingivitis (NUG) Market Size (2021-2032)
- 8.2 Europe Necrotizing Ulcerative Gingivitis (NUG) Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Necrotizing Ulcerative Gingivitis (NUG) Market Size by Country (2021-2026)
- 8.4 Europe Necrotizing Ulcerative Gingivitis (NUG) Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Necrotizing Ulcerative Gingivitis (NUG) Market Size (2021-2032)
- 9.2 Asia-Pacific Necrotizing Ulcerative Gingivitis (NUG) Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Necrotizing Ulcerative Gingivitis (NUG) Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Necrotizing Ulcerative Gingivitis (NUG) Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Necrotizing Ulcerative Gingivitis (NUG) Market Size (2021-2032)
- 10.2 South America Necrotizing Ulcerative Gingivitis (NUG) Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Necrotizing Ulcerative Gingivitis (NUG) Market Size by Country (2021-2026)
- 10.4 South America Necrotizing Ulcerative Gingivitis (NUG) Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Necrotizing Ulcerative Gingivitis (NUG) Market Size (2021-2032)
- 11.2 Middle East & Africa Necrotizing Ulcerative Gingivitis (NUG) Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Necrotizing Ulcerative Gingivitis (NUG) Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Necrotizing Ulcerative Gingivitis (NUG) Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Abbott Laboratories
- 12.1.1 Abbott Laboratories Company Information
- 12.1.2 Abbott Laboratories Business Overview
- 12.1.3 Abbott Laboratories Revenue in Necrotizing Ulcerative Gingivitis (NUG) Business (2021-2026)
- 12.1.4 Abbott Laboratories Necrotizing Ulcerative Gingivitis (NUG) Product Portfolio
- 12.1.5 Abbott Laboratories Recent Developments
- 12.2 Eli Lilly and Company
- 12.2.1 Eli Lilly and Company Company Information
- 12.2.2 Eli Lilly and Company Business Overview
- 12.2.3 Eli Lilly and Company Revenue in Necrotizing Ulcerative Gingivitis (NUG) Business (2021-2026)
- 12.2.4 Eli Lilly and Company Necrotizing Ulcerative Gingivitis (NUG) Product Portfolio
- 12.2.5 Eli Lilly and Company Recent Developments
- 12.3 Hindustan Antibiotics
- 12.3.1 Hindustan Antibiotics Company Information
- 12.3.2 Hindustan Antibiotics Business Overview
- 12.3.3 Hindustan Antibiotics Revenue in Necrotizing Ulcerative Gingivitis (NUG) Business (2021-2026)
- 12.3.4 Hindustan Antibiotics Necrotizing Ulcerative Gingivitis (NUG) Product Portfolio
- 12.3.5 Hindustan Antibiotics Recent Developments
- 12.4 Otsuka Pharmaceutical
- 12.4.1 Otsuka Pharmaceutical Company Information
- 12.4.2 Otsuka Pharmaceutical Business Overview
- 12.4.3 Otsuka Pharmaceutical Revenue in Necrotizing Ulcerative Gingivitis (NUG) Business (2021-2026)
- 12.4.4 Otsuka Pharmaceutical Necrotizing Ulcerative Gingivitis (NUG) Product Portfolio
- 12.4.5 Otsuka Pharmaceutical Recent Developments
- 12.5 GlaxoSmithKline
- 12.5.1 GlaxoSmithKline Company Information
- 12.5.2 GlaxoSmithKline Business Overview
- 12.5.3 GlaxoSmithKline Revenue in Necrotizing Ulcerative Gingivitis (NUG) Business (2021-2026)
- 12.5.4 GlaxoSmithKline Necrotizing Ulcerative Gingivitis (NUG) Product Portfolio
- 12.5.5 GlaxoSmithKline Recent Developments
- 12.6 Mylan
- 12.6.1 Mylan Company Information
- 12.6.2 Mylan Business Overview
- 12.6.3 Mylan Revenue in Necrotizing Ulcerative Gingivitis (NUG) Business (2021-2026)
- 12.6.4 Mylan Necrotizing Ulcerative Gingivitis (NUG) Product Portfolio
- 12.6.5 Mylan Recent Developments
- 12.7 Merck
- 12.7.1 Merck Company Information
- 12.7.2 Merck Business Overview
- 12.7.3 Merck Revenue in Necrotizing Ulcerative Gingivitis (NUG) Business (2021-2026)
- 12.7.4 Merck Necrotizing Ulcerative Gingivitis (NUG) Product Portfolio
- 12.7.5 Merck Recent Developments
- 12.8 Novartis
- 12.8.1 Novartis Company Information
- 12.8.2 Novartis Business Overview
- 12.8.3 Novartis Revenue in Necrotizing Ulcerative Gingivitis (NUG) Business (2021-2026)
- 12.8.4 Novartis Necrotizing Ulcerative Gingivitis (NUG) Product Portfolio
- 12.8.5 Novartis Recent Developments
- 12.9 Sanofi
- 12.9.1 Sanofi Company Information
- 12.9.2 Sanofi Business Overview
- 12.9.3 Sanofi Revenue in Necrotizing Ulcerative Gingivitis (NUG) Business (2021-2026)
- 12.9.4 Sanofi Necrotizing Ulcerative Gingivitis (NUG) Product Portfolio
- 12.9.5 Sanofi Recent Developments
- 12.10 Teva Pharmaceutical
- 12.10.1 Teva Pharmaceutical Company Information
- 12.10.2 Teva Pharmaceutical Business Overview
- 12.10.3 Teva Pharmaceutical Revenue in Necrotizing Ulcerative Gingivitis (NUG) Business (2021-2026)
- 12.10.4 Teva Pharmaceutical Necrotizing Ulcerative Gingivitis (NUG) Product Portfolio
- 12.10.5 Teva Pharmaceutical Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst